Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: Nationwide observational study emulating a randomised clinical trial

Hafsah Nabi*, Stylianos Georgiadis, Anne Gitte Loft, Oliver Hendricks, Dorte Vendelbo Jensen, Marlene Andersen, Stavros Chrysidis, Ada Colic, Kamilla Danebod, Mohamad Redha Hussein, Maren Høgberget Kalisz, Salome Kristensen, Niels Lomborg, Natalia Manilo, Heidi Lausten Munk, Jens Kristian Pedersen, Johnny Lillelund Raun, Frank Mehnert, Niels Steen Krogh, Merete Lund HetlandBente Glintborg

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

1 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
ISSN0003-4967
DOI
StatusE-pub ahead of print - 29 apr. 2021

Bibliografisk note

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: Nationwide observational study emulating a randomised clinical trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater